By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Release: Monthly Information Regarding The Total Number Of Voting Rights And Total Number Of Shares Of The Company 1/10/2017 11:10:43 AM
Ipsen (IPN.PA) To Acquire Oncology Assets From Merrimack (MACK) 1/9/2017 1:06:21 PM
Ipsen (IPN.PA) Amends Licensing Agreement With Exelixis (EXEL) To Commercialize And Develop Cabozantinib In Canada 12/22/2016 1:23:00 PM
Exelixis (EXEL) And Ipsen (IPN.PA) Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada 12/21/2016 9:29:26 AM
Claude Bertrand to Step Down as Executive Vice President, R&D and CSO of Ipsen (IPN.PA) 12/12/2016 6:19:31 AM
Ipsen (IPN.PA) Reports 12.2%1 Sales Growth For The Third Quarter Of 2016 And Raises Full Year Guidance 10/26/2016 10:06:31 AM
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At The European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016 11:55:27 AM
Exelixis (EXEL) And Ipsen (IPN.PA) To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress 10/4/2016 11:11:20 AM
Ipsen (IPN.PA) Announces Nine Poster Presentations At The 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium 9/30/2016 10:52:39 AM
Ipsen (IPN.PA) Announces Data Presentations Of Cabozantinib (Cabometyx), Lanreotide (Somatuline┬« Autogel┬«) And Telotristat Ethyl* At The European Society For Medical Oncology (ESMO) 2016 Congress 9/27/2016 10:57:15 AM